Abstract: |
This chapter examines the role of combined modality therapy in the treatment of locally advanced esophageal cancer. While surgery remains a cornerstone of treatment, pre- or peri-operative chemotherapy is associated with improved survival for patients with gastroesophageal junction (GEJ) adenocarcinoma histology. Primary chemoradiation is the accepted standard of care for medically inoperable patients. Definitive chemoradiation is acceptable for patients with squamous histology, while subsequent surgery improves local control without conferring a clear survival benefit. Recent studies show a clear benefit for pre-operative chemoradiation, which may be associated with several advantages over chemotherapy alone, including an improvement in the pathologic complete response rate and resectability, and reduction in local recurrence. Adjuvant chemoradiation may be considered for patients who undergo primary resection of GEJ adenocarcinoma. The optimal chemotherapy regimen with radiation remains undefined, and the evaluation of targeted agents has been disappointing. PET scans are being actively evaluated to guide therapy. © 2001, 2006, 2015 by John Wiley & Sons, Ltd. All rights reserved. |